Brain
- MELO-CARRILLO A, Strassman AM, Broide R, Adams A, et al
Novel insight into atogepant mechanisms of action in migraine prevention.
Brain. 2024 Feb 27:awae062. doi: 10.1093.
Cephalalgia
- PASCUAL-MATO M, Garate G, de Prado-Tejerina C, Garcia MJ, et al
Increased prevalence of migraine in women with inflammatory bowel disease: A
cross-sectional study.
Cephalalgia. 2024;44:3331024241233979.
- IKUMI N, Marti-Marca A, Torre-Sune A, Cerda-Company X, et al
Quantifying sensory thresholds along the migraine cycle: An exploratory
longitudinal study.
Cephalalgia. 2024;44:3331024241230279.
- TASSORELLI C, Onishchenko K, Halker Singh RB, Duan M, et al
Comparative efficacy, quality of life, safety, and tolerability of atogepant and
rimegepant in migraine prevention: A matching-adjusted indirect comparison
analysis.
Cephalalgia. 2024;44:3331024241235156.
- SHEWALE AR, Brandenburg JA, Burslem K, Lipton RB, et al
Health care resource utilization and costs associated with diagnosed medication
overuse headache and potential acute medication overuse in individuals with
migraine.
Cephalalgia. 2024;44:3331024241235139.
Headache
- SCUTELNIC A, Sutter NL, Beyeler M, Meinel TR, et al
Characteristics of acute ischemic stroke and unusual aura in patients with
migraine with aura.
Headache. 2024 Feb 27. doi: 10.1111/head.14682.
- CHHABRA N, Mead-Harvey C, Dodoo CA, Iser C, et al
Blood pressure elevation in erenumab-treated patients with migraine: A
retrospective real-world experience.
Headache. 2024 Feb 27. doi: 10.1111/head.14679.
-
Correction to: "Once-daily oral atogepant for the long-term preventive treatment
of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial".
Headache. 2024 Feb 26. doi: 10.1111/head.14691.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016